mycamine 50-10ml vial injection
astellas pharma inc., japan - micafungin - injection - 5 mg/ml
xtandi 40 mg
astellas pharma international b.v., israel - enzalutamide - capsules soft - enzalutamide 40 mg - enzalutamide - xtandi is indicated for:• the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc).• the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.• the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
xtandi 40 mg capsules
astellas pharma international b.v., israel - enzalutamide - capsules soft - enzalutamide 40 mg - enzalutamide - xtandi is indicated for:•the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc). •the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. •the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.• the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy
betmiga 25 mg
astellas pharma international b.v., israel - mirabegron - tablets prolonged release - mirabegron 25 mg - mirabegron - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (oab) syndrome
betmiga 25 mg
astellas pharma international b.v., israel - mirabegron - tablets prolonged release - mirabegron 25 mg - mirabegron - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (oab) syndrome
betmiga 50 mg
astellas pharma international b.v., israel - mirabegron - tablets prolonged release - mirabegron 50 mg - mirabegron - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (oab) syndrome
betmiga 50 mg
astellas pharma international b.v., israel - mirabegron - tablets prolonged release - mirabegron 50 mg - mirabegron - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (oab) syndrome
mycamine powder for solution for infusion 50mgvial
astellas pharma singapore pte. ltd. - micafungin sodium 50.86 mg equivalent to micafungin - injection, powder, lyophilized, for solution - 50 mg/vial - micafungin sodium 50.86 mg equivalent to micafungin 50 mg/vial
zineryt pdr+solv for cut soln
astellas pharma co. ltd - erythromycin, zinc acetate - pdr+solv for cut soln - 40 mg/ml,1 micromol - antiinfectives for treatment of acne
betmiga mirabegron 50 mg film-coated prolonged-release tablet blister pack
astellas pharma australia pty ltd - mirabegron, quantity: 50 mg - tablet, modified release - excipient ingredients: macrogol 2000000; macrogol 8000; purified water; butylated hydroxytoluene; hyprolose; magnesium stearate; hypromellose; iron oxide yellow - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (oab) syndrome.